Xeltis’ restorative approach in heart valve therapy is gaining momentum. A special issue of the peer-reviewed journal EuroIntervention, available this week at PCR London Valves 2017 meeting, features the outcomes from the first session dedicated to Endogenous Tissues Restoration (ETR) at the medical meeting EuroPCR (May 2017).
The paper illustrates how the restorative approach based on ETR may help overcome the limitations of heart valve options currently available. It further outlines the positive outcomes secured to date from preclinical and clinical trials of Xeltis’ investigational heart valves and blood vessels that enable ETR.
“The medical community’s increasing interest in ETR confirms the value of the growing body of evidence Xeltis is building through preclinical and clinical trials, as well as the potential of a restorative approach to solve the issues that patients with heart valve replacement face today,” commented Xeltis CTO Martijn Cox.
